Diabetes patients taking NovoLog® (HCPCS Level II code S5551 Insulin, most rapid onset (Lispro or Aspart); 5 units) can now use the insulin in their pump for up to six days. Diabetes care company Novo Nordisk announced Food and Drug Administration (FDA) approval of this labeling change July 21. The previous label allowed for NovoLog® to be stored in the pump reservoir for two days.

The updated label also states patients using NovoLog® in their pumps should change the infusion set and the infusion set insertion site at least every three days. The previous label stated that NovoLog® in the pump reservoir, infusion set and the infusion set insertion site be changed at least every 48 hours.

Add a Comment

Name (required)

Email Address (will not be published) (required)

Attention: AAPC does not regularly monitor comments posted here. For customer service issues, contact us. In addition, we recommend posting your questions to the AAPC forums.

CAPTCHA Code *